| Metric | Grade | Score | Evidence & Context | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 62 | High-growth healthcare tech with severe profitability headwinds offsetting strong YoY expansion and multi-year momentum. Hyper-growth flag active; strong balance sheet absent. Beta 2.11 signals elevated volatility; week52 return of +269.6% reflects speculative re-rating. | 6–12M |
| Growth Sustainability & Moat | B– | 75 | Revenue growth YoY: +20.2% confirms active demand in portable ultrasound segment. Hyper-growth flag active. Limited visibility on competitive moat; no forward guidance disclosed. Sector (Health Care / Medical Devices) offers moderate structural tailwinds. | 6–12M |
| Valuation & Safety (Pre-Penalty) | D+ | 45 | P/E unavailable (EPS: –$0.30, GAAP unprofitable). Forward P/E, target price, and TTM revenue not disclosed. Enterprise Value $1,873M against negative earnings and unspecified forward guidance creates valuation opacity. Market cap suggests premium pricing relative to profitability. | 1–3M |
| Earnings Momentum (Zacks Proxy) | D | 40 | EPS: –$0.30 (negative). EPS growth YoY not disclosed. Earnings date not available. Strong profitability flag: FALSE. Absence of earnings estimate revisions and forward guidance limits momentum visibility. | 1–3M |
| Institutional & Smart Money Flow | C | 58 | Week52 return: +269.6% indicates speculative inflow and momentum-driven accumulation. Average volume: 7.66M (modest for $1.9B market cap). Recent price action (–0.98% today, open $7.15) shows volatility. No insider trading or institutional ownership data; inferred neutral-to-cautious positioning given profitability gap. | 1–3M |
| Volatility & Drawdown Risk | D+ | 48 | Beta: 2.11 (highly volatile, ~2x market). Week52 range: $1.32–$9.69 (634% spread) reflects extreme drawdown risk. Current price ($7.10) near upper range. High downside asymmetry risk in growth-equity correction scenario. | 6–12M |
| Penalty Overlay | –15 pts | –15 | Applied: Negative EPS (–$0.30) and zero profitability (-10 pts). Hyper-growth w/o profitability and weak balance sheet signals (-5 pts). Disclosure gaps (earnings, forward guidance) (-2 pts). High valuation opacity (–3 pts). | 6–12M |
| Confidence Score | B– | 72 | LIVE_DATA completeness: 70%. Core quote and recent metrics solid. Major gaps: earnings date, target price, TTM revenue, forward estimates. Sector fundamentals and growth narrative clear; profitability transition timeline obscured. | 6–12M |
| Quality/Value Composite (S&A Proxy) | D+ | 49 | Quality component (profitability, balance sheet): LOW. Value component (valuation multiple): OPAQUE. Combined institutional score penalized by earnings deficit and premium-market positioning relative to near-term cash-generation metrics. | 1–3M |
BFLY operates in the portable/point-of-care ultrasound device segment, competing with established OEMs (GE Healthcare, Philips, Mindray) and emerging rivals. The 20.2% revenue growth YoY is competitive for medtech scale-ups, though profitability remains a critical gap. Hyper-growth classification aligns with early commercialization phase. Absence of dividend yield and weak balance sheet signals suggest reinvestment posture typical of pre-breakeven hardware/software hybrid vendors. Week52 performance (+269.6%) reflects sector rotation into digital health and remote diagnostics, but elevated beta (2.11) and wide valuation range ($1.32–$9.69) indicate sentiment volatility and crowding risk in growth-stage healthcare equities.
Verdict: CAUTIOUS. Short-term momentum remains positive (+20.2% revenue growth), but negative EPS and absent earnings guidance introduce event risk. Price action today (–0.98%) signals profit-taking or sector headwinds. With beta 2.11, expect continued intraday/weekly volatility. Average volume (7.66M) adequate for entry but insufficient for large institutional positions; liquidity concentration may amplify drawdowns. No earnings catalyst disclosed; watch for product launches or clinical partnership announcements.
Verdict: CONDITIONAL HOLD. Growth momentum (+20.2% revenue YoY) and hyper-growth flag support intermediate accumulation IF profitability pathway crystallizes within next 2–3 quarters. Valuation opacity (no forward P/E, target price, or earnings guidance) creates material uncertainty. Upside case: scaled adoption in enterprise/hospital networks, software-as-a-service monetization, margin expansion. Downside case: competitive intensity, reimbursement delays, macro tightening constraining growth. Current week52 range ($1.32–$9.69) and 269.6% YTD return suggest elevated crowding risk; institutional entry likely better timed on 15–25% pullback to $5.50–$6.00.
BFLY Stock Analysis & Forecast
Is BFLY a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
BFLY Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, BFLY shows balanced risk-reward characteristics.
Should You Buy BFLY Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in BFLY.